Taysha Gene Therapies (TSHA) Net Equity Issued and Repurchased (2020 - 2022)

Taysha Gene Therapies (TSHA) reported Net Equity Issued and Repurchased of $40000.0 for Q2 2022, down 99.94% sequentially from $66.2 million in Q4 2020.

Taysha Gene Therapies (TSHA) Net Equity Issued and Repurchased (2020 - 2022) Analysis & Trends

Taysha Gene Therapies (TSHA) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $40000.0 in Q2 2022.

  • For the quarter ending Q2 2022, Net Equity Issued and Repurchased changed N/A year-over-year to $40000.0; the trailing twelve-month figure through Sep 2023 stood at $40000.0 (down 99.95% YoY), and the FY2023 full-year result was $500000.0, down 95.7% from the prior year.
  • Net Equity Issued and Repurchased eased to $40000.0 in Q2 2022, from $66.2 million in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $66.2 million in Q4 2020 to a low of $40000.0 in Q2 2022.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Taysha Gene Therapies 2.14 Bn 2.14 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2022 40,000.00
Jun 30, 2022 40,000.00
Dec 31, 2020 66.25 Mn
Dec 31, 2020 66.25 Mn
Sep 30, 2020 10.97 Mn
Sep 30, 2020 10.97 Mn
Jun 30, 2020 600,000.00
Jun 30, 2020 600,000.00
Mar 31, 2020 18.00 Mn
Mar 31, 2020 18.00 Mn